204 related articles for article (PubMed ID: 6182575)
1. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors.
Wachtel H
Psychopharmacology (Berl); 1982; 77(4):309-16. PubMed ID: 6182575
[TBL] [Abstract][Full Text] [Related]
2. Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors.
Wachtel H
J Neural Transm; 1983; 56(2-3):139-52. PubMed ID: 6190991
[TBL] [Abstract][Full Text] [Related]
3. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo.
Wachtel H
J Pharm Pharmacol; 1983 Jul; 35(7):440-4. PubMed ID: 6136585
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant properties of some phosphodiesterase inhibitors.
Przegaliński E; Bigajska K
Pol J Pharmacol Pharm; 1983; 35(3):233-40. PubMed ID: 6194518
[TBL] [Abstract][Full Text] [Related]
6. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.
Wachtel H
Neuropharmacology; 1983 Mar; 22(3):267-72. PubMed ID: 6302550
[TBL] [Abstract][Full Text] [Related]
7. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
8. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
9. Delayed stimulation of bone resorption in vitro by phosphodiesterase inhibitors requires the presence of adenylate cyclase stimulation.
Ransjö M; Fredholm BB; Lerner UH
Bone Miner; 1988 Jan; 3(3):225-34. PubMed ID: 2462948
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
Hatzelmann A; Tenor H; Schudt C
Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
[TBL] [Abstract][Full Text] [Related]
11. Rat homologs of the Drosophila dunce gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20-1724.
Henkel-Tigges J; Davis RL
Mol Pharmacol; 1990 Jan; 37(1):7-10. PubMed ID: 2153912
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of two phosphodiesterase inhibitors on fat cell metabolism.
Shechter Y
Endocrinology; 1984 Nov; 115(5):1787-91. PubMed ID: 6208014
[TBL] [Abstract][Full Text] [Related]
13. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
14. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors.
Wachtel H; Schneider HH
Neuropharmacology; 1986 Oct; 25(10):1119-26. PubMed ID: 2946976
[TBL] [Abstract][Full Text] [Related]
15. Effects of inhibitors of cyclic nucleotide phosphodiesterase on actions of cholecystokinin, bombesin, and carbachol on pancreatic acini.
Gardner JD; Sutliff VE; Walker MD; Jensen RT
Am J Physiol; 1983 Nov; 245(5 Pt 1):G676-80. PubMed ID: 6195928
[TBL] [Abstract][Full Text] [Related]
16. The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration.
Knapp CM; Foye MM; Ciraulo DA; Kornetsky C
Pharmacol Biochem Behav; 1999 Jan; 62(1):151-8. PubMed ID: 9972858
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.
Marivet MC; Bourguignon JJ; Lugnier C; Mann A; Stoclet JC; Wermuth CG
J Med Chem; 1989 Jul; 32(7):1450-7. PubMed ID: 2544722
[TBL] [Abstract][Full Text] [Related]
18. Effects of forskolin on spontaneous behavior, rectal temperature and brain cAMP levels of rats: interaction with rolipram.
Wachtel H; Löschmann PA; Schneider HH; Rettig KJ
Neurosci Lett; 1987 May; 76(2):191-6. PubMed ID: 3035438
[TBL] [Abstract][Full Text] [Related]
19. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities.
Lugnier C; Gauthier C; Le Bec A; Soustre H
Am J Physiol; 1992 Mar; 262(3 Pt 2):H654-60. PubMed ID: 1373036
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term rolipram administration on the sensitivity of alpha 2-adrenoceptors in rat brain.
Mustafa MR; Stolz JF; Luscombe DK
Eur J Pharmacol; 1988 Mar; 148(2):171-7. PubMed ID: 2454198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
